Puma Biotech races ahead 190% after-hours

July 22, 2014 10:33 PM

15 0

Puma Biotechnology shares soared more than 190% to $173 .30 in after-hours trading Tuesday, buoyed by positive trial tests results of its breast cancer treatment.

Puma said 2,841 patients diagnosed with early stage breast cancer who had undergone surgery were part of its Phase 3 clinical trials of Neratinib.

Also read: Shopping-Mall Operator Westfield Agrees to Takeover Bid Valuing It at $15.7 Billion

Read more

To category page